CytRx Corp. (CYTR)

1.31
0.04 2.60
NASDAQ : Health Technology
Prev Close 1.35
Open 1.33
Day Low/High 1.30 / 1.34
52 Wk Low/High 1.24 / 5.99
Volume 209.50K
Avg Volume 371.50K
Exchange NASDAQ
Shares Outstanding 33.64M
Market Cap 44.74M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CytRx Corporation To Present At OneMed NYC Oncology Investor Conference 2018

New President and Chief Operating Officer Mr. Eric Curtis will be Representing CytRx Corporation

CytRx Corporation Names Eric L. Curtis As Its President And Chief Operating Officer

Seasoned Professional with 25 Years of Experience in Both Oncology and Orphan Diseases, Including Development and Commercialization of Approved Drugs Votrient®, Doxil®, Velcade® and Benlysta®

CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical Trials

CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates For Advancement Toward Clinical Trials

Supportive Data on All Candidates to be Highlighted in Poster Presentations at the Upcoming American Association for Cancer Research 2018 Annual Meeting Next Month

CytRx Announces Key Addition To Corporate Development Team

CytRx Announces Key Addition To Corporate Development Team

Company Engages Expert Advisor Eric L. Curtis to Lead Internal Development Efforts and Manage External Partner Relationships

CytRx Announces The Presentation Of New LADR™ Candidate Data At The American Association For Cancer Research 2018 Annual Meeting

CytRx Announces The Presentation Of New LADR™ Candidate Data At The American Association For Cancer Research 2018 Annual Meeting

All Three Studies Submitted Were Selected for Poster Presentations

Interesting CYTR Call Options For March 2018

Interesting CYTR Call Options For March 2018

Investors in CytRx Corp saw new options begin trading today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Goodbye CytRx, Your Game Is Over

Goodbye CytRx, Your Game Is Over

Hope springs eternal, until it's dashed on the rocks and buried at sea.

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

First Week of CYTR September 15th Options Trading

First Week of CYTR September 15th Options Trading

Investors in CytRx Corp saw new options begin trading this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx announced a plan Tuesday to seek U.S. marketing approval of aldoxorubicin based more on hocus-pocus than credible study results.

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

TheStreet Quant Rating: D- (Sell)